LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Lista de Ações・Kura Oncology Inc

Kura Oncology Inc

Fechado

SetorSaúde

10.24 -1.54

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.24

Máximo

10.54

Indicadores-chave
By Trading Economics
Rendimento	7.7M -73M
Vendas	929K 18M
EPS	-0.828
Margem de lucro	-401.495
Funcionários	260
EBITDA	7.4M -78M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+170.03% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	159M 1B
Abertura anterior	11.78
Fecho anterior	10.24

Sentimento de Notícias

By Acuity

26%

74%

47 / 344 Ranking em Healthcare

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mai. de 2026, 21:33 UTC

Ganhos

Correction to Salesforce 1Q Sales, Profit Rise Article

27 de mai. de 2026, 21:00 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 de mai. de 2026, 20:18 UTC

Ganhos

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 de mai. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de mai. de 2026, 23:08 UTC

Conversa de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 de mai. de 2026, 22:21 UTC

Conversa de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 de mai. de 2026, 21:29 UTC

Ações em Alta

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 de mai. de 2026, 21:08 UTC

Ganhos

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 de mai. de 2026, 21:02 UTC

Ganhos

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 de mai. de 2026, 20:59 UTC

Aquisições, Fusões, Aquisições de Empresas

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 de mai. de 2026, 20:55 UTC

Ganhos

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de mai. de 2026, 20:48 UTC

Ganhos

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 de mai. de 2026, 20:45 UTC

Ganhos

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 de mai. de 2026, 20:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Webster Financial Stockholders Approve Sale to Banco Santander

27 de mai. de 2026, 20:32 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 de mai. de 2026, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 de mai. de 2026, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 de mai. de 2026, 20:30 UTC

Ganhos

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 de mai. de 2026, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 de mai. de 2026, 20:22 UTC

Ganhos

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 de mai. de 2026, 20:16 UTC

Ganhos

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 de mai. de 2026, 20:13 UTC

Ganhos

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 de mai. de 2026, 20:13 UTC

Ganhos

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 de mai. de 2026, 20:13 UTC

Ganhos

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 de mai. de 2026, 20:12 UTC

Ganhos

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 de mai. de 2026, 20:12 UTC

Ganhos

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

170.03% parte superior

Previsão para 12 meses

Média 28.11 USD 170.03%

Máximo 40 USD

Mínimo 15 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

47 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.